SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Concealed Drug Risks: Levi & Korsinsky

Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities class action lawsuit alleging that the company and its officers concealed material safety risks associated with its product DCCR during the class period from March 26, 2025, to November 4, 2025 [2][7]. Group 1: Company Overview - Soleno's sole commercial product, VYKAT XR, was approved by the FDA on March 26, 2025, to treat hyperphagia in individuals with Prader-Willi syndrome [2]. - The lawsuit claims that Soleno made materially misleading statements regarding DCCR's safety profile and commercial viability, while concealing evidence of serious adverse events [5]. Group 2: Legal Proceedings - The U.S. District Court for the Northern District of California has set May 5, 2026, as the deadline for institutional investors to apply for lead plaintiff appointment in the class action [2]. - The action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of all purchasers of Soleno common stock during the specified class period [7]. Group 3: Institutional Investor Considerations - Institutional investors who acquired SLNO shares during the class period may have fiduciary obligations to evaluate the pursuit of a lead plaintiff role [3]. - The PSLRA favors institutional investors with the largest financial interest in the relief sought by the class, and lead plaintiffs have the authority to select and oversee class counsel [7][8].